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Castration-resistant prostate cancer remains an incurable
disease. The unmet clinical need to optimally select individual
treatment options, and thereby maximize survival benefit, can
be addressed by patient-specific preclinical models. Patient-
derived organoids preserve original tumor characteristics
and have shown potential for high-throughput assessments
and coclinical drug testing, as highlighted for several cancer
types in this review. This new patient-derived 3D culture
technique and its downstream applications are the subjects
of intense investigation in prostate cancer. Although chal-
lenges are not trivial, we expect a major impact on prostate
cancer research, with a window of opportunities for early
bench-to-bedside translation of new drug discoveries and
guidance of patient-tailored disease management.
Addresses
Department of Urology, Erasmus University Medical Center, P.O. Box
2040, 3000 CA, Rotterdam, the Netherlands
Corresponding author: van Weerden Wytske M (w.vanweerden@
erasmusmc.nl)Current Opinion in Endocrine and Metabolic Research 2020,
10:7–15
This review comes from a themed issue on Prostate cancer
Edited by Zoran Culig
For a complete overview see the Issue and the Editorial
Available online 19 February 2020
https://doi.org/10.1016/j.coemr.2020.02.005
2451-9650/© 2020 The Authors. Published by Elsevier Ltd. This is an
open access ar ticle under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords
Prostate cancer, Organoids, Personalized medicine, Drug screens.Introduction
In recent years substantial advances have been made in
local and systemic therapies for prostate cancer (PC),
but nonetheless it remains a lethal disease. Although a
majority of patients can be treated with curative intent,
those presenting with advanced, metastatic, recurrent or
progressive disease eventually develop incurable
castration-resistant prostate cancer (CRPC). Several
new agents for treating CRPC have been introducedwww.sciencedirect.com Crecently and additional novel agents are under investi-
gation [1]. Despite these successes in PC drug devel-
opment, mortality rates are only slowly declining in
Western countries [2]. To date, the optimal treatment
sequence and/or optimal drug combination(s) to achieve
maximal survival benefit in this subset of patients re-
mains unclear [1,3]. Moreover, cross-resistance between
different drugs has been described, influencing the
potential benefit of subsequent treatments [1,4,5]. The
ability to select the optimal (next line) treatment for
individual CRPC patients is an unmet clinical need that
could potentially be tackled by representative patient-
specific preclinical models. Such experimental models
will help our understanding in the development of
CRPC, the mechanisms of cross-resistance and the
optimal sequential or combinational use of available
agents.
The establishment of in vitro and in vivo patient-derived
PC models has proven to be very difficult, with long
latency times and very low success rates [6e8]. Hence,
preclinical PC research has predominantly been foun-
ded on a limited number of in vitro PC cell lines, with
three patient-derived lines (PC-3, DU-145, and
LNCaP) dominating the field [6,7]. Although these cell
lines have been instrumental for many developments in
PC research, they are limited in their reflection of the
actual clinical disease, with two of the cell lines lacking
androgen receptor (AR) expression, the key driver of PC
development and progression [6]. Despite obvious ad-
vantages of 2D model systems (e.g., ease in handling,
propagation, and maintenance, limited costs), they are
compromised by serious limitations, such as aberrant
cell behavior regarding cell morphology, polarity, prolif-
eration and migration as a consequence of artificial
growth as a monolayer on plastic, absent 3D structure,
lack of extracellular matrix, cell-matrix, and cellecell
interactions [7].
Our group and others worldwide have taken the effort to
generate human PC patient-derived xenografts (PDXs),
with an overall take rate of 10e40% (for a complete
overview of internationally available PC PDXs we refer
to Navone et al. [8]). These preclinical mouse models
more accurately retain the histologic, molecular, and
genetic characteristics of the primary patient tumor, and
predict patient drug responses more precisely compared
to 2D cell lines [9e11]. Although the relevance of PDXsurrent Opinion in Endocrine and Metabolic Research 2020, 10:7–15
8 Prostate cancerin PC research is well established, their use is limited to
low-throughput assessments and is associated with sig-
nificant ethical, regulatory, facility, financial, and inter-
species concerns.
In recognition of these limitations, novel patient-
derived 3D culture technologies are under investiga-
tion, aiming to fill the gap between or even replace
traditional cancer cell lines and PDXs. Organoids have
been shown to maintain patient-specific phenotypic and
genetic characteristics [12,13]. Combined with their
suitability for high-throughput screening approaches
[13], these new techniques can pave the way to early
bench-to-bedside translation and personalized medi-
cine. Although a clear consensus is lacking on what to
call a spheroid or an organoid, we here define organoids
as 3D self-organizing organotypic structures cultured in
a 3D matrix [13].
In this review, we explore the possibilities for applying
current scaffold-based organoid culture techniques
specifically in human prostate cancer, a notoriously
difficult cancer to culture in vitro. We discuss current
insights, applications and challenges of primary patient-
derived PC organoids in preclinical research and for early
bench-to-bedside translation, as well as the use of PC
PDXs, as an intermediate step to generate human PC
organoids. These PDXs constitute an indefinite source
of human tumor tissue that allows for the
necessary optimization of PC organoid culture methods
and downstream processing protocols.Figure 1
Schematic workflow for generating prostate cancer patient-derived organoids
proaches (Created with BioRender.com).
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A major advance in the organoid culture technology was
achieved by Sato et al., in 2009 [14]. In groundbreaking
research, they were able to grow villus-like intestine
epithelial organoids by seeding Lgr5-positive mouse
intestinal stem cells in Matrigel overlaid with medium
supplemented with epidermal growth factor (EGF), R-
spondin 1 and Noggin [14]. Since then, the organoid
research field has dramatically evolved, with the estab-
lishment of long-term patient-derived organoids
(PDO) from various healthy [12] and cancerous [13,15]
human tissues. In general, following the procurement of
a patient sample, (pathologically assessed) tissue pieces
are dissected and subjected to enzymatic digestion.
Dissociated cells are then incorporated into a basement
membrane matrix and covered with tissue-specific
medium (Figure 1).
Initial efforts in PC research, using normal prostate
tissue from radical prostatectomy (RP) specimens,
resulted in human prostate organoids that were cultured
for >12 months, without obvious phenotypical or ge-
netic changes over time [16]. Prostate epithelial orga-
noids formed cystic structures composed of an outer
basal layer and an inner luminal layer, thus displaying an
architecture that resembles prostate glands in vivo [16].
Applying this approach to generate renewable primary
cancer organoids, however, failed due to overgrowth by
normal prostate epithelial cells present within each
tumor sample [16]. In a parallel study, Gao et al.and downstream applications. Dotted lines represent alternative ap-
www.sciencedirect.com
Table 1
Primary patient-derived prostate cancer organoids.
Author Sample origin Success
Rate (%)
Number of Organoid
Lines Reported
Tissue origin of organoid line In vitro maintenance Organoid Classification
Gao et al., 2014 [17] Distant metastases (32 attempts:
18 bone, 9 lymph node, 2 liver,
1 brain, 1 bladder,
1 pleural effusion)
18,75%(6/32
attempts)
6 Bone (2), lymph node (2),
pleural effusion (1),
bladder (1)
>6 months - Intraductal carcinoma
- Adenocarcinoma
(high-grade; mucinous;
Gleason 4 with cribriform
growth; adenocarcinoma
with extensive squamous
differentiation)
- NE tumor
~ 30% NR Bone 1–2 months NR
~ 70% NR Soft tissue 1–2 months NR
Blood (17 attempts) 5% (1/17
attempts)
1 CTCs >6 months NR
Puca et al.,
2018 [18]
Distant metastases
(34 attempts)
11,75%(4/34
attempts)
4 Liver (1), lymph node (1),
soft tissue (1), sternum (1)
median 12 months
Passage 10
NE tumors (pure small
cell carcinoma and
high-grade carcinoma
with extensive
neuroendocrine
differentiation)
61%(21/34
attempts)
21 NR Passage <10 NR
Welti et al.,
2018 [19]
Distant metastases
(36 attempts)
61%(22/36
attempts)
9 lines available for
growth experiments
of 7 days
Lymph node (5),
bone marrow (4)
NR NR
Beshiri et al.,
2018 [24]
Distant metastases NR 4 Spine (1), neck (2), liver (1) Passage>6 - AR + adenocarcinoma
- AR + carcinoma with
NE features
- AR- carcinoma without
NE features
Shenoy et al.,
2017 [25]
Distant metastases (bone,
lymph node, liver)
NR 5 NR NR NR
Lambros et al.,
2018 [26]
Blood NR 2 CTCs NR NR
NR = not reported; NE = neuroendocrine; CTCs = circulating tumor cells; AR = androgen receptor; CRPC = castration resistant prostate cancer.
3D
cu
ltu
re
m
o
d
els
o
f
p
ro
state
can
cer
V
an
H
em
elryk
and
van
W
eerden
9
w
w
w
.sciencedirect.com
C
u
rren
t
O
p
in
io
n
in
E
n
d
o
crin
e
an
d
M
etab
o
lic
R
esearch
2020,
10:7
–
15
10 Prostate cancersuccessfully generated a panel of seven human prostate
cancer organoid lines, using metastatic biopsies and
circulating tumor cells, therefore avoiding the presence
of normal prostate epithelium. These organoids were
continuously propagated for >6 months and demon-
strated to harbor known genetic alterations associated
with PC [17]. More recently, Puca and colleagues re-
ported on the establishment of four neuroendocrine PC
organoid lines derived from needle biopsies of meta-
static lesions [18]. Organoids were propagated for a
median of 12 months. All four lines lacked AR expres-
sion, but expressed classical neuroendocrine markers,
thus representing rather rare late-stage PC phenotypes
[18]. In both reports, PC organoids displayed (immuno)
histological characteristics present in the original pa-
tient samples [17,18].
Overall, success rates for generating long-term primary
patient-derived PC organoid cultures are low and seem
to be dependent on starting material, ranging from 10 to
20% in metastatic biopsies [17,18], over 5% in circu-
lating tumor cells [17] to 0% in RP samples [16].
Nevertheless, it is worth mentioning that success rates
for establishing short-term primary PC PDOs are
markedly higher, ranging from 60 to 70% [17e19]
(Table 1).
Alternatively, human tumor organoids can be generated
from PDX tumor tissue [20e22]. Beshiri et al. reported
on a PDX-derived organoid biobank to model advanced
PC subtypes, by processing 20 LuCaP CRPC PDX
models, including adenocarcinoma and neuroendocrine
tumors [23,24]. Proliferative organoids were established
from all 20 PDXs, and 11 of them were amenable for
long-term propagation (>10 organoid passages). Short-
term PDX-derived organoids preserved the character-
istic genomic features of the original PDX [24].Figure 2
Phase-contrast image (left), hematoxylin, and eosin-stained histological section
receptor (right) of a PC PDX-derived organoid (unpublished data).
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Prostate cancer is primarily an androgen driven disease,
with androgen deprivation therapy (ADT) founding the
treatment of advanced and metastatic disease [4,27].
Inevitably, tumors acquire resistance to castration, but
even in this castration-resistant state, AR remains the
key driver of PC progression as the majority of tumors
remains dependent on AR signaling for their growth and
survival, making the AR pathway a major target for
subsequent treatments [1,28,29]. A prerequisite for
preclinical models to represent the clinical disease,
therefore, involves the presence and activity of this
pathway. Organoids derived from AR-positive PC pa-
tients, or PDXs, have shown to preserve an active AR
signaling pathway (Figure 2) and/or castration driven AR
alterations, making them suitable for AR targeting drug
screens and studying resistance mechanisms [17,24].
Welti et al. were the first to use CRPC patient and PDX-
derived organoids exhibiting AR mutations, AR ampli-
fication, and AR-V7 protein expression to investigate the
effect of bromodomain and extra-terminal (BET) pro-
tein inhibitors on aberrant AR signaling in CRPC. They
reported a growth-inhibitory effect upon the treatment
of these organoids, supporting the ongoing clinical
studies of BET inhibitors in CRPC patients [19].
Additional to the dominant role of the AR pathway,
whole-exome and genome sequencing of metastatic
CRPC sample sets revealed that a large subset of these
patients harbors additional (potentially actionable) ab-
errations in other cancer-related genes [29,30]. Reports
on PDOs of various cancer types, including PC, show
genomic consistency with the original patient or PDX
tumor from which the organoids were derived
[13,17,18,24,31e33]. This strongly supports the appli-
cation of PDOs for the in vitro testing of relevant,
targeted therapies. Recently, Marzi et al. reported on(middle), and positive immunohistochemical staining of nuclear androgen
www.sciencedirect.com
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deficient PC PDX-derived organoids [34]. Shenoy and
colleagues generated PDOs from CRPC patients with
and without CHD1 loss, a common genomic alteration
in PC, and showed its relationship to sensitivity to DNA
damaging therapy [25].
In spite of the limited number of compounds and PC
organoids included in these first drug testing studies, a
major advantage of PDOs is their potential suitability for
high-throughput drug screening. This approach is
currently under intense exploration in various cancer
types, including PC. Some early successes of tumor
organoid-based (semi-) high-throughput screens [31e
33,35] suggest that this platform could similarly be
highly promising in PC research. Jansson et al. reported
on the first attempt in PC, by performing a screen on 15
PDX-derived PC organoids using 110 drugs/compounds
[36].Personalized medicine and coclinical
applications
With treatment strategies for advanced PC becoming
increasingly diverse, the need quickly arises for
personalized medicine [1]. This need, however, is not
exclusive to PC and has been a major focus of cancer
researchers over recent years. Tumor genomics alone is
insufficient to identify optimal therapeutic options for
many advanced cancer types, suggesting the need for
parallel preclinical drug testing to personalize medicine
[37]. Vlachogiannis and colleagues reported on a living
biobank of colorectal and gastroesophageal cancer
organoids and compared organoid responses to targeted
agents or chemotherapy with the responses of matched
patients. They observed 100% sensitivity, 93% speci-
ficity, 88% positive predictive value, and 100% negative
predictive value for organoids to forecast responses in
patients [38]. In parallel studies, Tiriac and colleagues
generated a pancreatic cancer PDO library and estab-
lished a drug-testing pipeline to generate druge
sensitivity profiles for each organoid. By retrospec-
tively analyzing a small subset of patients from whom
the organoids were established, they showed that orga-
noid chemotherapy sensitivity profiles reflect matched
patient responses [39]. Recently, in a multicenter pro-
spective study, colorectal cancer organoids were able to
accurately predict response in >80% of patients treated
with the chemotherapeutic irinotecan. However, orga-
noids failed to predict the outcome for other included
chemotherapeutics, with the lack of tumor micro-
environment suggested by the authors as one possible
reason for this failure [40]. In another study, Ganesh
et al. generated 65 patient-derived rectal cancer orga-
noids and demonstrated that organoid responses to
clinically relevant chemotherapy and radiation treat-
ment correlated with clinical responses in individual
patients [41]. Very interestingly, a proof of concept inwww.sciencedirect.com Cusing PC organoids to predict drug responses in
matched patients was recently published by Beltran and
colleagues [42]. Organoids from two patients with
neuroendocrine PC, one exceptional responder and one
nonresponder to alisertib, demonstrated a similar trend
in response compared to the corresponding patients
[42]. Overall, this data suggests that organoids,
including PC organoids, can recapitulate patient re-
sponses, and therefore, might be suited to guide clinical
decision-making.Challenges and discussion
CRPC remains an incurable disease, and optimal treat-
ment strategies to maximize survival benefit remain
unclear [1]. PDOs that preserve patient-specific tumor
characteristics and allow high-throughput screening
approaches might pave the way to an early bench-to-
bedside translation of new drug discoveries and
personalized medicine.
Although the establishment of primary patient-derived
organoids from various cancer types is well described,
limited successes have been achieved in generating long-
term PDOs from PC [16e18]. There are several reasons
for this limited success. First, as experienced by other
groups and us, prostate tumor cells exhibit low prolifer-
ation rates, and initial cultures easily become overtaken
by noncancerous cells [16e18]. After dissection and
digestion of a tumor sample, all cells present in the
starting material are embedded in basement membrane
matrix, including tumor-associated spindle cells and
normal epithelial cells (e.g., normal prostate cells in RP
samples or normal epithelial cells present in metastatic
biopsies, e.g., lung or liver cells), which easily overgrow
PC cells in vitro [16,17]. It is unfortunate that detailed
information on the persistent presence of these noncan-
cerous cells in long-term cultures is lacking in the original
papers [16e18]. Secondly, the availability of PC samples
with high tumor cell load is particularly limited as
(skeletal bone) metastatic sampling is invasive and is not
standard of care. Samples from RP or transurethral
resection of the prostate (TURP) are more commonly
available, but present difficulties in selecting for tumor
organoids during in vitro culturing, as a robust PC
selectable marker is lacking and normal prostate organo-
ids tend to dominate the cultures (16, unpublished data).
Finding the missing link that would enable substantial
improvements towards successful in vitro PC culture re-
mains a vital concern. Extensive efforts by us and others
are directed to fulfill this quest through testing of various
manipulable factors, including physical factors, such as
oxygenation and pressure, medium components, co-
cultures with cancer-associated fibroblasts, and condi-
tional reprogramming [24,43e47].
As an alternative, human PC organoids can be cultured
with higher efficiency from PC PDX tissue [24], whichurrent Opinion in Endocrine and Metabolic Research 2020, 10:7–15
12 Prostate canceris composed of human tumor cells without the presence
of human normal epithelial cells. The extensive number
of publically available PC PDXs [8] holds the promise
that generating a PC organoid panel that reflects a wide
diversity of clinical tumors is feasible and this consti-
tutes one of our current aims. By representing several
PC patient subtypes, these PDX-derived organoids can
be exploited to study mechanisms of cross-resistance, to
determine optimal sequential and/or combinational use
of existing drugs and to test relevant, targeted therapies
within these subtypes. Moreover, they can serve as a
base to pioneer organoid-based high-throughput drug
discovery. Although the organoid culture technology
itself is gradually becoming custom, its downstream
drug testing and screening applications are still under
full development. Preliminary results of large-scale drug
screens on organoids are so far encouraging but are
exclusively founded on ATP-based cell viability assays
(CellTiter-Glo, Promega) [32,33,35,36]. Besides these
measurements, phenotypic profiling using additional
alternative screening approaches, such as high-content
imaging (Figure 3), will contribute to the assessment
of more complex biological responses that may better
correlate with clinical endpoints. If we can further
improve existing success rates for short-term primary
patient-derived PC organoids and in parallel develop
pipelines to perform large-scale drug testing on these
early cultures, we believe this approach could eventually
lead the way to personalized medicine.
First coclinical trials to test the feasibility of using
organoids for predicting drug responses in matched pa-
tients yielded promising results [38e42]. However, for
PC, there are still some challenges. As PC is typically a
slow-growing tumor in vitro, the feasibility to generate,Figure 3
High-content live-cell imaging as an additional approach for organoid-based d
staining using Calcein AM, Propidium Iodide and SiR-DNA nuclear staining of u
of an untreated PC organoid (3D projection); (c): Selection of individual cell n
published data).
Current Opinion in Endocrine and Metabolic Research 2020, 10:7–15expand, and screen primary patient-derived organoids
within a clinically relevant time frame needs consider-
ation. Also, the heterogeneity of the disease brings the
risk of sample bias and/or in vitro selection of subclones
[48]. Both may result in the incomplete coverage of the
full tumor heterogeneity within a single patient, with
the consequence of inaccurate prediction of drug
response [49]. Although genomic profiles of PDOs
showed high concordance to those of the original
tumors, several studies have reported differences,
confirming selective representation of the patients’
disease [33,49e51]. Also, evaluation of genomic changes
during long-term PDO propagation is crucial, as
genomic drift in cancer models is inevitable [51,52].
Clearly, the way for coclinical trials in PC is to focus on
short-term primary PDOs and their feasibility to predict
patient responses to conventional treatments (i.e., anti-
androgens and chemotherapeutics), eventually allowing
for more efficient clinical decision making. In parallel,
efforts for long-term cultures should aim to generate a
biobank representing relevant subtypes of PC that will
further aid fundamental and early translational research.
Finally, current organoid cultures are reported to
exclusively contain epithelial constituents [13].
Although these epithelial organoids preserve cellecell
interactions, 3D tumor morphology, and cell-matrix in-
teractions, they still lack critical cell type and supportive
stroma components that are assumed to impact tumor
behavior and drug response [53,54]. New culture tech-
niques are rapidly advancing to coculture epithelial
tumor organoids with various cell types (e.g., stroma
[43,55], immune cells [56], bone [57], lung, and
endothelial cells [58]), to fully recapitulate the complex
in vivo tumor micro-environment.rug screening. (a): Single plane confocal image displaying live/dead cell
ntreated PC cell line-derived organoids; (b): Long-term time-lapse imaging
uclei within a PC organoid as a basis for downstream 3D analysis (un-
www.sciencedirect.com
3D culture models of prostate cancer Van Hemelryk and van Weerden 13Overall, PC PDOs are not without limitations and joint
efforts are vital to tackle current challenges. Organoid
cultures are likely to stay and may hold great promises in
the PC research field. We envision future guidance of
patient-tailored disease management by preclinical drug
testing in PDOs combined with genomic tumor
profiling, that will ultimately meet the clinical need for
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